[1]张 超,李 非,李 昂,等.肝动脉化疗栓塞治疗原发病灶切除的胰腺神经内分泌肿瘤肝转移疗效分析[J].介入放射学杂志,2020,29(08):772-776.
 ZHANG Chao,LI Fei,LI Ang,et al.Transcatheter arterial chemoembolization for neuroendocrine tumor liver metastasis after resection of primary tumor: analysis of curative effect[J].journal interventional radiology,2020,29(08):772-776.
点击复制

肝动脉化疗栓塞治疗原发病灶切除的胰腺神经内分泌肿瘤肝转移疗效分析()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
29
期数:
2020年08
页码:
772-776
栏目:
肿瘤介入
出版日期:
2020-08-25

文章信息/Info

Title:
Transcatheter arterial chemoembolization for neuroendocrine tumor liver metastasis after resection of primary tumor: analysis of curative effect
作者:
张 超 李 非 李 昂 罗 涛 曹 锋 李 钰 孙瑛璠 崔 丽 段 峰
Author(s):
ZHANG Chao LI Fei LI Ang LUO Tao CAO Feng LI Yu SUN Yingfan CUI Li DUAN Feng.
Department of General Surgery, Xuanwu Hospital of Capital Medical University, Beijing 100053,China
关键词:
【关键词】 肝肿瘤肿瘤转移 胰腺神经内分泌瘤 栓塞治疗性
文献标志码:
A
摘要:
【摘要】 目的 探讨TACE对于已经切除原发病灶的胰腺神经内分泌肿瘤肝转移(neuroendocrine neoplasm liver metastasis, NELM)的疗效。方法 回顾分析2014年6月至2018年6月诊治的21例胰腺NELM患者入组进行研究,所有病例均行原发病灶切除后针对肝脏病灶进行65例次TACE治疗。分析临床疗效,安全性和有效性;根据影像学检查后实体瘤反应评价标准评价病灶疗效;并随访无疾病生存期(PFS)和总生存期(OS)情况。 结果 所有患者均顺利完成TACE治疗,有效率为81.0%(17/21);影像学评价中17例达到部分缓解,3例病情稳定,1例出现疾病进展;PFS为(16.6±6.5)个月,OS为(28.0±11.8)个月,所有手术均未出现严重并发症。 结论 TACE治疗原发病灶切除后的胰腺NELM安全有效,其可能因降低肿瘤负荷、阻断分泌功能提高总生存率而获得更多获益。

参考文献/References:

[1] WHO Classification of Tumors Editorial Board. WHO Classifi- cation of Tumours. Digestive System Tumours[M]. Fifth Edition, United States: IARC Publications, 2019.
[2] Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases[J]. Lancet Oncol, 2014, 15: e8- e21.
[3] Okuyama H, Ikeda M, Takahashi H, et al. Transarterial(chemo)embolization for liver metastases in patients with neuroendocrine tumors[J]. Oncology, 2017, 92: 353- 359.
[4] 刘一铭. 肝动脉栓塞术联合长效奥曲肽降低中低级别神经内分泌瘤肝转移负荷的疗效及安全性分析[J]. 中华医学杂志, 2019, 99:1142- 1146
[5] Frilling A, Sotiropoulos GC, Li J, et al. Multimodal management of neuroendocrine liver metastases[J]. HPB(Oxford), 2010, 12: 361- 379.
[6] Zuo MX, Huang JH. The history of interventional therapy for liver cancer in China[J]. J Interventl Med, 2018, 1: 70- 76.
[7] Lau W Y, Lai ECH. Loco- regional intervention for hepatocel-lular carcinoma[J]. J Intervent Med, 2019, 2: 43- 46.
[8] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors and Adrenal Tumors[M]. Fort Washington: NCCN, 2019.
[9] Kitano M, Davidson GW, Shirley LA, et al. Transarterial chemoembolization for metastatic neuroendocrine tumors with massive hepatic tumor burden: is the benefit worth the risk? [J]. Ann Surg Oncol, 2016, 23: 4008- 4015.
[10] Dhir M, Shrestha R, Steel JL, et al. Initial treatment of unresectable neuroendocrine tumor liver metastases with transarterial chemoembolization using streptozotocin: a 20- year experience[J]. Ann Surg Oncol, 2017, 24: 450- 459.
[11] de Baere T, Deschamps F, Tselikas L, et al. GEP- NETS update: interventional radiology: role in the treatment of liver metastases from GEP- NETs[J]. Eur J Endocrinol, 2015, 172: R151- R166.
[12] Do Minh D, Chapiro J, Gorodetski B, et al. Intra- arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug- eluting beads TACE and yttrium- 90 radioembolisation as treatment options using a propensity score analysis model[J]. Eur Radiol, 2017, 27: 4995- 5005.
[13] 李晓光, 金征宇, 潘 杰, 等. 肝动脉化疗或栓塞治疗胰腺神经内分泌肿瘤肝转移的疗效分析[J]. 介入放射学杂志, 2010, 19: 442- 446.
[14] Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroen- docrine tumors in the United States[J]. JAMA Oncol, 2017, 3: 1335- 1342.
[15] Grozinsky- Glasberg S, Kaltsas G, Kaltsatou M, et al. Hepatic intra- arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice[J]. Endocrine, 2018, 60: 499- 509.
[16] 房星宇, 于 淼, 杨倚天, 等. 肝动脉化疗栓塞及射频消融治疗胰腺神经内分泌肿瘤肝转移的疗效和生存分析[J]. 介入放射学杂志, 2013, 22: 377- 380.
[17] 刘秋松, 张恭良, 李彦豪, 等. 肝脏神经内分泌肿瘤血管造影表现与生存分析[J]. 介入放射学杂志, 2017, 26: 318- 322.
[18] Oberg K, Knigge U, Kwekkeboom D, et al. Neuroendocrine gastro- entero- pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow- up[J]. Ann Oncol, 2012, 23:124- 130.
[19]中国临床肿瘤学会神经内分泌肿瘤专家委员会. 中国胃肠胰神经内分泌肿瘤专家共识(2016年版)[J]. 临床肿瘤学杂志, 2016, 10: 927- 946.
[20] Hur S, Chung J W, Kim HC, et al. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases[J]. J Vasc Interv Radiol, 2013, 24: 947- 957.

相似文献/References:

[1]周建勤,董伟华,欧阳强,等.入经肺动脉灌注碘油对肺转移瘤的血供研究[J].介入放射学杂志,2008,(08):570.
 ZHOU Jianqin,DONG Weihua,OUYANG Qiang,et al.Study on blood supply of lung metastasis with trans-pulmonary arterial lipiodol infusion[J].journal interventional radiology,2008,(08):570.
[2]李国文,梁赵玉,于小平,等.肝转移瘤血供对肝动脉化疗栓塞的近期疗效影响[J].介入放射学杂志,2010,(06):493.
 LI Guowen,LIANG Zhaoyu,YU Xiaoping,et al.The influence of blood supply pattern of hepatic metastases on the short-term effect of TACE[J].journal interventional radiology,2010,(08):493.
[3]赵进委,蒋国民,陈亚贤,等.肺转移瘤的支气管动脉造影血供分析[J].介入放射学杂志,2007,(05):320.
 ZHAO Jin-wei,JIANG Guo-ming,CHEN Ya-xian,et al.Evaluation of blood supply of pulmonary metastasis by using bronchial artery angiography[J].journal interventional radiology,2007,(08):320.
[4]杜 鲲,管 生,胡小波,等. 原发性肝癌TACE术后完全缓解病灶磁共振 ADC值可重复性及一致性研究[J].介入放射学杂志,2011,(11):867.
 DU Kun,GUAN Sheng,HU Xiao-bo,et al.Magnetic resonance apparent diffusion coefficient values of the completely remitted lesions of primary hepatocellular carcinoma after TACE: a study of their repeatability and consistency[J].journal interventional radiology,2011,(08):867.
[5]李建军,郑加生,崔雄伟,等. 肝肿瘤CT引导经皮射频消融术后胆道并发症防治[J].介入放射学杂志,2011,(12):984.
 LI Jian-jun,ZHENG Jia-sheng,CUI Xiong-wei,et al.The prevention and treatment of biliary complications occurred after CT-guided percutaneous radiofrequency ablation for hepatic neoplasms[J].journal interventional radiology,2011,(08):984.
[6]张学彬,花迎雪,仇晓霞,等. 肝动脉臭氧化碘油栓塞治疗兔VX2肝癌的初步研究[J].介入放射学杂志,2012,(09):760.
 ZHANG Xue- bin,HUA Ying-xue,QIU Xiao- xia,et al. A preliminary study of hepatic arterial embolization with ozonated?蛳 Lipiodol for liver VX2 carcinoma in experimental rabbits[J].journal interventional radiology,2012,(08):760.
[7]钱 亭,陈茂振,高 峰,等. 两种方法建立兔VX2肝癌模型的比较及影像学评估[J].介入放射学杂志,2014,(01):58.
 QIAN Ting,CHEN Mao? zhen,GAO Feng,et al. Comparison of two methods used in establishing VX?蛳 2 liver tumor model in rabbits and their imaging evaluation[J].journal interventional radiology,2014,(08):58.
[8]徐守军,杜端明,刘鹏程,等. 肝肿瘤射频消融术后CT表现及其临床意义[J].介入放射学杂志,2014,(01):69.
 XU Shou? jun,DU Duan? ming,LIU Peng? cheng,et al. CT manifestation and its clinical significance of liver tumors after radiofrequency ablation[J].journal interventional radiology,2014,(08):69.
[9]陈文会,杨朝爱,杨继金,等. 曲马多在经皮穿刺肝肿瘤射频消融术中的应用[J].介入放射学杂志,2014,(02):126.
 CHEN Wen? hui,YANG Chao? ai,YANG Ji? jin,et al. Application of tramadol in performing percutaneous radiofrequency ablation for liver neoplasms[J].journal interventional radiology,2014,(08):126.
[10]陈长广,倪才方,陈 珑. 肝动脉栓塞联合射频消融对兔肝癌模型VEGF及MVD的影响[J].介入放射学杂志,2013,(11):936.
 CHEN Chang? guang,NI Cai? fang,CHEN Long.. Effect of transcatheter arterial chemoembolization together with radiofrequency ablation on VEGF and MVD in rabbit models with hepatic cancer[J].journal interventional radiology,2013,(08):936.

备注/Memo

备注/Memo:
(收稿日期:2020- 02- 13)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2020-08-16